Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDT Conduit Pharmaceuticals	$1.67 -8.2%	$2.25	$1.64 ▼ $274.80	$5.33M	1.93	101,256 shs	150,553 shs
INAB IN8bio	$2.40 +4.8%	$2.30	$1.98 ▼ $21.21	$6.93M	0.01	116,202 shs	62,392 shs
INDP Indaptus Therapeutics	$7.81 -7.5%	$9.98	$6.65 ▼ $58.24	$4.83M	1.14	9,430 shs	6,517 shs
PPBT Purple Biotech	$2.31 +3.6%	$2.40	$2.00 ▼ $13.95	$5.77M	0.49	269,162 shs	13,996 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDT Conduit Pharmaceuticals	-8.24%	-10.70%	-26.43%	-71.45%	-99.25%
INAB IN8bio	+4.80%	+11.63%	+11.11%	-37.84%	-86.67%
INDP Indaptus Therapeutics	-7.46%	+15.88%	-35.93%	-37.88%	-83.40%
PPBT Purple Biotech	+3.59%	+7.44%	-6.85%	+1.76%	+230,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CDT Conduit Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
INAB IN8bio	4.0447 of 5 stars	3.5	5.0	0.0	0.0	3.9	2.5	1.3
INDP Indaptus Therapeutics	3.2399 of 5 stars	3.5	5.0	0.0	0.0	1.0	1.7	1.3
PPBT Purple Biotech	2.2227 of 5 stars	3.5	2.0	0.0	0.0	3.2	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CDT Conduit Pharmaceuticals	0.00	N/A	N/A	N/A
INAB IN8bio	3.00	Buy	$180.00	7,400.00% Upside
INDP Indaptus Therapeutics	3.00	Buy	$238.00	2,947.38% Upside
PPBT Purple Biotech	3.00	Buy	$33.00	1,328.57% Upside

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CDT Conduit Pharmaceuticals	N/A	N/A	N/A	N/A	($73.54) per share	N/A
INAB IN8bio	N/A	N/A	N/A	N/A	$5.04 per share	N/A
INDP Indaptus Therapeutics	N/A	N/A	N/A	N/A	$10.84 per share	N/A
PPBT Purple Biotech	N/A	N/A	N/A	N/A	$12.40 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CDT Conduit Pharmaceuticals	-$17.80M	-$534.48	N/A	∞	N/A	N/A	N/A	-435.57%	N/A
INAB IN8bio	-$30.44M	-$9.11	N/A	N/A	N/A	N/A	-184.97%	-126.75%	N/A
INDP Indaptus Therapeutics	-$15.02M	-$41.74	N/A	N/A	N/A	N/A	-399.14%	-242.40%	N/A
PPBT Purple Biotech	-$7.24M	-$0.42	N/A	N/A	N/A	N/A	-14.00%	-12.52%	8/15/2025 (Estimated)

Latest CDT, PPBT, INDP, and INAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/15/2025	N/A	PPBT Purple Biotech	-$0.21	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	CDT Conduit Pharmaceuticals	N/A	-$5.46	N/A	-$5.46	N/A	N/A
8/13/2025	Q2 2025	INDP Indaptus Therapeutics	-$0.36	-$9.09	-$8.73	-$9.09	N/A	N/A
8/7/2025	Q2 2025	INAB IN8bio	-$1.50	-$1.24	+$0.26	-$1.24	N/A	N/A
8/6/2025	Q2 2025	PPBT Purple Biotech	-$0.21	-$0.40	-$0.19	-$0.40	N/A	N/A
5/21/2025	Q1 2025	PPBT Purple Biotech	N/A	-$0.17	N/A	-$0.17	N/A	N/A
5/15/2025	Q1 2025	CDT Conduit Pharmaceuticals	N/A	-$19.80	N/A	-$1.32	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CDT Conduit Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
INAB IN8bio	N/A	N/A	N/A	N/A	N/A
INDP Indaptus Therapeutics	N/A	N/A	N/A	N/A	N/A
PPBT Purple Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CDT Conduit Pharmaceuticals	N/A	1.31	1.31
INAB IN8bio	0.01	7.03	7.03
INDP Indaptus Therapeutics	N/A	1.90	1.90
PPBT Purple Biotech	N/A	2.88	2.88

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CDT Conduit Pharmaceuticals	3.29%
INAB IN8bio	92.05%
INDP Indaptus Therapeutics	7.06%
PPBT Purple Biotech	9.64%

Insider Ownership

Company	Insider Ownership
CDT Conduit Pharmaceuticals	7.72%
INAB IN8bio	15.50%
INDP Indaptus Therapeutics	20.80%
PPBT Purple Biotech	2.98%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CDT Conduit Pharmaceuticals	3	2.93 million	2.70 million	Not Optionable
INAB IN8bio	20	3.03 million	2.56 million	Not Optionable
INDP Indaptus Therapeutics	6	570,000	454,000	Not Optionable
PPBT Purple Biotech	20	2.59 million	2.51 million	Optionable

CDT, PPBT, INDP, and INAB Headlines

Recent News About These Companies

Purple Biotech (PPBT) to Release Quarterly Earnings on Friday

August 13 at 2:20 AM | americanbankingnews.com

Purple Biotech (NASDAQ:PPBT) Shares Down 4.9% After Earnings Miss

August 8, 2025 | americanbankingnews.com

Purple Biotech Reports Second Quarter 2025 Financial Results

August 6, 2025 | globenewswire.com

Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025

July 23, 2025 | globenewswire.com

Purple Biotech Stock Price History - Investing.com

July 8, 2025 | investing.com

Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress

June 23, 2025 | globenewswire.com

Purple Biotech Announces Initiation of Phase 2 Study of NT219 in Patients with Head and Neck Cancer

June 17, 2025 | finance.yahoo.com

Purple Biotech Announces Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody Platform

June 4, 2025 | finance.yahoo.com

H.C. Wainwright Raises Purple Biotech (PPBT) Price Target, Reiterates Buy Rating

June 1, 2025 | msn.com

Purple Biotech Ltd.: Purple Biotech Reports First Quarter 2025 Financial Results

May 21, 2025 | finanznachrichten.de

Purple Biotech Reports First Quarter 2025 Financial Results

May 21, 2025 | globenewswire.com

Purple Biotech Appoints Shai Lankry as Chief Financial Officer to Drive Strategic Growth and Financial Excellence

May 13, 2025 | nasdaq.com

Purple Biotech appoints Shai Lankry as new CFO

May 13, 2025 | investing.com

Purple Biotech Ltd.: Purple Biotech Appoints Shai Lankry as Chief Financial Officer

May 12, 2025 | finanznachrichten.de

Purple Biotech Appoints Shai Lankry as Chief Financial Officer

May 12, 2025 | globenewswire.com

Purple Biotech Unveils Promising Phase 2 Results for CM24 in Pancreatic Cancer

April 30, 2025 | tipranks.com

Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers

April 28, 2025 | globenewswire.com

Purple Biotech announces publication of study on potential of NT219

April 17, 2025 | markets.businessinsider.com

Purple Biotech Announces Three Posters Accepted for Presentation at the 2025 American Association for Cancer Research Meeting

March 28, 2025 | finance.yahoo.com

Purple Biotech Unveils Updated Oncology Pipeline Progress

March 18, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDT, PPBT, INDP, and INAB Company Descriptions

Conduit Pharmaceuticals NASDAQ:CDT

$1.67 -0.15 (-8.24%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$1.65 -0.02 (-0.96%)

As of 08:00 AM Eastern

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.

IN8bio NASDAQ:INAB

$2.40 +0.11 (+4.80%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$2.39 -0.01 (-0.42%)

As of 08:00 AM Eastern

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Indaptus Therapeutics NASDAQ:INDP

$7.81 -0.63 (-7.46%)

Closing price 08/14/2025 03:59 PM Eastern

Extended Trading

$7.74 -0.06 (-0.83%)

As of 07:48 AM Eastern

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Purple Biotech NASDAQ:PPBT

$2.31 +0.08 (+3.59%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$2.31 0.00 (-0.22%)

As of 08:00 AM Eastern

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time